

CORE STORY

# Theralase Technologies Inc.

Theralase Technologies Inc. is a bio-tech company with two highly-innovative divisions. The Company's PDT Division is devoted to producing a cancer cure via Photo Dynamic Therapy for various forms of cancer. This involves two elements:

- 1) Selecting the correct wavelength of laser light at an intensity level which does not damage healthy tissue.
- 2) Developing an activation compound, a Photo Dynamic Compound ("PDC"), which can penetrate cancer cells and then eradicate them from within via a photo-chemical reaction.

After more than \$30 million in research investment, Theralase produced TLD-1433, for use in the treatment of Non-Muscle Invasive Bladder Cancer ("NMIBC"). The advantage of this PDC is that it responds to different wavelengths of laser light, so it can be utilized at varying tissue depths. The other advantage of TLD-1433 is that it can be modified for use with other types of cancer, saving the time/expense/effort of developing a completely new PDC.

The Company has already combined TLD-1433 with transferrin to produce a new compound suitable for use in treating, Glioblastoma Multiforme (GBM), brain cancer. A Phase Ib clinical (human) trial has already commenced with respect to NMIBC and a Phase Ib clinical trial for GBM is expected to commence toward the end of 2017. Phase II clinical trials are targeted to begin at some time in 2018.

In addition to being highly effective in destroying cancer cells, PDT therapy also teaches the body to fight that type of cancer cells via an immune system response. Thus PDT therapy is akin to a cancer vaccine (for that form of cancer).

Theralase's other division is its TLT Division – Therapeutic Light Therapy. This branch of the Company's operations is devoted to pain management and the healing of injuries. The pain management market is a \$100+ billion per year industry in the U.S. alone, with more than 100 million Americans having enduring pain issues of one form or another.

## HIGHLIGHTS

- Two, innovative hi-tech divisions: PDT and TLT
- Developed procedure and PDC (TLD-1433) for the treatment of NMIBC, now in Phase Ib clinical trial
- Modified TLD-1433 for use in treatment of GBM, Phase Ib clinical trial scheduled to commence in Q4 2017
- Developed (first) the TLC-1000 and (now) the TLC-2000 as commercial applications of Therapeutic Light Therapy
- To better capture the revenue potential of this technology, the Company has developed a monthly leasing business model

## GOALS AND OBJECTIVES

- Successful completion of Phase Ib clinical trial for NMIBC therapy
- Progress to Phase II (larger scale) clinical trial for NMIBC therapy
- Successful completion of Phase Ib clinical trial for GBM therapy
- Hire and deploy additional sales managers to expedite market penetration of TLC-2000

CORE STORY

# Theralase Technologies Inc.

Theralase has already commercialized this branch of its business through (first) the TLC-1000 and (now) the Theralase 2000. To better capture the revenue potential for this technology with the more advanced TLC-2000, the Company has initiated a monthly leasing program.

## AD MESSAGING

### Pioneering a cure for cancer

- Highly innovative laser therapy technology
- Overwhelming preliminary success in laboratory testing
- Clinical human trials have now commenced
- Creates natural resistance, like cancer vaccine

### Bringing pain-management solution to \$100+ B market

- Uses super-pulsed laser technology
- Highly effective, drug-free pain relief
- Also used to heal professional athletes' injuries

Using a Trojan Horse to cure cancer

Cancer is TOUGH to kill externally...

TLD-1433 penetrates cancer cells...

And it kills cancer from the INSIDE OUT